Abstract

RAMIREZ, Sergio Francisco et al. Neuroleptic malignant syndrome with central pontine myelinolysis. Acta Neurol Colomb. [online]. 2018, vol.34, n.4, pp.245-249. ISSN 0120-8748.  https://doi.org/10.22379/24224022221.

Neuroleptic malignant syndrome (NMS) is a severe complication of antipsychotics, especially those of first generation such as haloperidol, which was the first in which this pathology was described, characterized by: fever, rigidity, alteration of the state of consciousness and dysautonomies. On the other side, central pontine myelinolysis (Now Called Osmotic Demyelination Syndrome), search results of acute sodium alterations of sodium, as those occurring in hyponatremia replenings and could put life at risk just like the NMS. The association of these two pathologies is unusual and until now, their causal relationship, the result of the few cases reported, is not clearly known. Although the relationship of the neurological syndrome may be limited, the company of central myelolysis could increase the morbidity of this entity, so it is necessary to be required quickly to prevent the onset of complications, which does not have a specific treatment. We present the case of a young patient who has these pathologies and we consider that the cause of centralized myelinolysis is haloperidol as well as NMS, despite this, this medication continues to be very safe in clinical practice since the appearance of These complications is an idiosyncratic reaction due to some type of unknown genetic susceptibility.

Keywords : antipsychotic agents; haloperidol; myelinolysis, central pontine; neuroleptic malignant syndrome (MeSH).

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )